摘要
目的:观察更昔洛韦治疗小儿传染性单核细胞增多症的临床疗效和安全性。方法:将确诊为传染性单核细胞增多症的32例患儿随机分为治疗组16例和对照组16例,对照组给予利巴韦林10~15 mg/(kg·d)静脉滴注,每天1次,治疗组给予更昔洛韦5 mg/(kg·d)静脉滴注,每12 h 1次,两组疗程均为7~10 d,比较两组患儿临床症状消退时间、有效率和不良反应发生情况等。结果:两组发热、咽峡炎、肝脾淋巴结肿大恢复时间比较,治疗组较对照组明显缩短,差异有统计学意义(P〈0.05);治疗组总有效率93.8%,对照组总有效率75.0%,两组比较差异有统计学意义(P〈0.05);在治疗观察期间更昔洛韦治疗组未见明显不良反应。结论:更昔洛韦治疗小儿传染性单核细胞增多症可明显缩短热程,减轻症状,安全有效,值得推广。
Objective: To investigate the efficacy and safety of ganciclovir in children with infectious mononucleosis. Methods: Thirty-two cases with infectious mononucleosis were randomly divided into two groups: the treatment group (n = 16) treated with ganciclovir 5 rag/(kg · d) intravenous drip; the control group (n = 16 ) treated with ribavirin 10 ~ 15 mg/( kg · d ) intravenous drip. The clinical symptoms, efficacy and adverse reactions were compared between the two groups. Results: The recovery length of fever, angina, liver, spleen and lymph nodes enlargements in the treatment group were shorter than those in the control group; the difference was statistically significant (P〈0.05). The total effective rate of the treatment group was 93.0% , while of the control group it was 75.0% , the difference between the two groups was statistically significant (P〈0.05). There were no adverse reactions observed in the group treated with ganciclovir. Conclusions: Ganciclovir is effective and safe in treating children with infectious mononucleosis.
出处
《儿科药学杂志》
CAS
2013年第12期22-23,共2页
Journal of Pediatric Pharmacy